Year |
Citation |
Score |
2024 |
Seedhom MO, Dersh D, Holly J, Pavon-Eternod M, Wei J, Angel M, Shores L, David A, Santos J, Hickman H, Yewdell JW. Paradoxical imbalance between activated lymphocyte protein synthesis capacity and rapid division rate. Elife. 12. PMID 38512721 DOI: 10.7554/eLife.89015 |
0.646 |
|
2023 |
Dersh D, Yewdell JW. SUS(d6)pending MHC class I peptide presentation for cancer immunoevasion. Cell Research. PMID 37833358 DOI: 10.1038/s41422-023-00882-4 |
0.593 |
|
2023 |
Papadaki GF, Ani O, Florio TJ, Young MC, Danon JN, Sun Y, Dersh D, Sgourakis NG. Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules. Frontiers in Immunology. 14: 1116906. PMID 36761745 DOI: 10.3389/fimmu.2023.1116906 |
0.476 |
|
2021 |
Huang S, Zhang W, Katanski CD, Dersh D, Dai Q, Lolans K, Yewdell J, Eren AM, Pan T. Interferon inducible pseudouridine modification in human mRNA by quantitative nanopore profiling. Genome Biology. 22: 330. PMID 34872593 DOI: 10.1186/s13059-021-02557-y |
0.424 |
|
2021 |
Dersh D, Yewdell JW. Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation. The Journal of Clinical Investigation. 131. PMID 33393509 DOI: 10.1172/JCI144344 |
0.559 |
|
2020 |
Dersh D, Phelan JD, Gumina ME, Wang B, Arbuckle JH, Holly J, Kishton RJ, Markowitz TE, Seedhom MO, Fridlyand N, Wright GW, Huang DW, Ceribelli M, Thomas CJ, Lack JB, et al. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity. PMID 33271120 DOI: 10.1016/j.immuni.2020.11.002 |
0.647 |
|
2020 |
Dersh D, Hollý J, Yewdell JW. Author Correction: A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nature Reviews. Immunology. PMID 32873889 DOI: 10.1038/S41577-020-00445-3 |
0.579 |
|
2020 |
Dersh D, Hollý J, Yewdell JW. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nature Reviews. Immunology. PMID 32820267 DOI: 10.1038/S41577-020-0390-6 |
0.662 |
|
2020 |
Jia L, Mao Y, Ji Q, Dersh D, Yewdell JW, Qian SB. Decoding mRNA translatability and stability from the 5' UTR. Nature Structural & Molecular Biology. PMID 32719458 DOI: 10.1038/S41594-020-0465-X |
0.552 |
|
2019 |
Yewdell JW, Dersh D, Fåhraeus R. Peptide Channeling: The Key to MHC Class I Immunosurveillance? Trends in Cell Biology. PMID 31662235 DOI: 10.1016/J.Tcb.2019.09.004 |
0.686 |
|
2019 |
Dersh D, Yewdell JW, Wei J. A SIINFEKL-Based System to Measure MHC Class I Antigen Presentation Efficiency and Kinetics. Methods in Molecular Biology (Clifton, N.J.). 1988: 109-122. PMID 31147936 DOI: 10.1007/978-1-4939-9450-2_9 |
0.632 |
|
2019 |
Wei J, Kishton RJ, Angel M, Conn CS, Dalla-Venezia N, Marcel V, Vincent A, Catez F, Ferré S, Ayadi L, Marchand V, Dersh D, Gibbs JS, Ivanov IP, Fridlyand N, et al. Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. Molecular Cell. PMID 30712990 DOI: 10.1016/J.Molcel.2018.12.020 |
0.737 |
|
2017 |
Wei J, Zanker D, Di Carluccio AR, Smelkinson MG, Takeda K, Seedhom MO, Dersh D, Gibbs JS, Yang N, Jadhav A, Chen W, Yewdell JW. Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands. Journal of Immunology (Baltimore, Md. : 1950). PMID 28363906 DOI: 10.4049/Jimmunol.1602122 |
0.627 |
|
2016 |
Dersh D, Yewdell JW. I've got algorithm: predicting tumor and autoimmune peptide targets for CD8+ T cells. The Journal of Clinical Investigation. 126: 4399-4401. PMID 27841762 DOI: 10.1172/Jci91302 |
0.631 |
|
Show low-probability matches. |